Results 51 to 60 of about 71,028 (295)
Background Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) competes with CD28 for binding CD80/CD86 on antigen-presenting cells (APCs) to limit T cell activation.
Po-Chun Liu +7 more
doaj +1 more source
Bacteria‐Trained, MnO2‐Armored Dendritic Cells for Immunotherapy
MnO2‐armored, bacteria‐trained dendritic cells undergo tumor‐responsive mechanical and immunological transformation. The nanocoating masks immune ligands and maintains a mechanically stiff, quiescent state during circulation, while the tumor microenvironment removes the armor and restores cellular deformability and immune accessibility.
Zhao Guo +9 more
wiley +1 more source
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin +20 more
wiley +1 more source
Autoantibodies against CD80 in patients with COPD
Chronic obstructive pulmonary disease (COPD) is an inflammation disorder and possibly an autoimmune disease. The components of the autoimmune response in the circulatory system are of considerable interest to clinicians. Because aberrations of costimulation status have been noted in COPD, the presence of autoantibodies to B7 costimulatory factor CD80 ...
Luo, Xu Min +6 more
openaire +2 more sources
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang +8 more
wiley +1 more source
Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection.
BackgroundThe failure to establish potent anti-HBV T cell responses suggests the absence of an effective innate immune activation. Kupffer cells and liver-infiltrating monocytes/macrophages have an essential role in establishing anti-HBV responses. These
Elias A Said +9 more
doaj +1 more source
Acquisition of CD80 (B7-1) by T Cells [PDF]
Abstract Activation of T cells usually requires two signals. Signal 1 is mediated via a peptide-MHC on the APC; signal 2 is mediated via a costimulatory molecule on the APC surface. We demonstrate here that naive CD4+ T cells actually acquire the costimulatory molecule CD80 (B7-1) from syngeneic APCs after activation.
H, Sabzevari +7 more
openaire +2 more sources
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee +6 more
wiley +1 more source
Photodynamic therapy (PDT) with redaporfin stimulates colon carcinoma (CT26), breast (4T1) and melanoma (B16F10) cells to display high levels of CD80 molecules on their surfaces. CD80 overexpression amplifies immunogenicity because it increases same cell
Catarina S. Lobo +4 more
doaj +1 more source
Minimal Change Disease: A CD80 podocytopathy?
Minimal change disease is the most common nephrotic syndrome in children. Although the etiology of minimal change disease remains to be elucidated, it has been postulated that it is the result of a circulating T-cell factor that causes podocyte cytoskeleton disorganization leading to increased glomerular capillary permeability and/or changes in ...
Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, CO ( host institution ) +6 more
openaire +3 more sources

